These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37958408)

  • 21. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer.
    Kroese TE; Buijs GS; Burger MDL; Ruurda JP; Mook S; Brosens LAA; van Rossum PSN; van Hillegersberg R
    Ann Surg Oncol; 2022 Aug; 29(8):4848-4857. PubMed ID: 35381938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy.
    Chen HJ; Tu CY; Hsia TC; Fang HY; Chen CH; Chen SC; Li CH; Liao YM; Hsieh CY; Lein MY; Liang JA; Chien CR
    Anticancer Res; 2020 Oct; 40(10):5895-5899. PubMed ID: 32988920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
    Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
    Front Oncol; 2020; 10():987. PubMed ID: 32676455
    [No Abstract]   [Full Text] [Related]  

  • 25. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
    Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.
    Tsur E; Blumenfeld P; Rottenberg Y; Nechushtan H; Arnon J; Wald O; Izhar U; Pfeffer R; Krakow A; Wygoda M; Popovtzer A; Michaeli TF
    Transl Lung Cancer Res; 2024 Mar; 13(3):465-474. PubMed ID: 38601442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.
    Mielgo-Rubio X; Garde-Noguera J; Juan O; Couñago F
    World J Clin Oncol; 2020 Dec; 11(12):983-989. PubMed ID: 33437660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
    Kroese TE; Bronzwaer S; van Rossum PSN; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds JV; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshoff MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs C; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen GAP; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Tabernero J; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Laarhoven HWM; van Hillegersberg R;
    Eur J Cancer; 2024 Jun; 204():114062. PubMed ID: 38678762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changing equipoise in the landscape of radiation for oligometastatic lung cancer.
    Schroeder SR; Leenders M; Iyengar P; de Ruysscher D
    Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S184-S191. PubMed ID: 31673523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
    Piroth MD; Krug D; Feyer P; Baumann R; Combs S; Duma MN; Dunst J; Fastner G; Fietkau R; Guckenberger M; Haase W; Harms W; Hehr T; Sedlmayer F; Souchon R; Strnad V; Budach W
    Strahlenther Onkol; 2022 Jul; 198(7):601-611. PubMed ID: 35527272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature.
    Schanne DH; Heitmann J; Guckenberger M; Andratschke NHJ
    Cancer Treat Rev; 2019 Nov; 80():101892. PubMed ID: 31522079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
    Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
    Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligoprogression in non-small cell lung cancer: a narrative review.
    Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
    J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
    Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
    Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
    Huynh MA; Tang C; Siva S; Berlin A; Hannan R; Warner A; Koontz B; De Meeleer G; Palma D; Ost P; Tran PT
    Eur Urol Oncol; 2023 Feb; 6(1):28-38. PubMed ID: 36283936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
    Kroese TE; van Laarhoven HWM; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds J; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshof MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs CT; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen G; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Hillegersberg R; van Rossum PSN;
    Eur J Cancer; 2023 May; 185():28-39. PubMed ID: 36947929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions.
    Couñago F; Luna J; Guerrero LL; Vaquero B; Guillén-Sacoto MC; González-Merino T; Taboada B; Díaz V; Rubio-Viqueira B; Díaz-Gavela AA; Marcos FJ; Del Cerro E
    World J Clin Oncol; 2019 Oct; 10(10):318-339. PubMed ID: 31799148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.